Floatz logo

OPICINUMAB

Central Nervous System (CNS) Demyelinating Disease

Biogenmonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Central Nervous System (CNS) Demyelinating Disease cohort.

Asset / SponsorPhaseRating
CLEMASTIN
University of California, San Francisco
Phase 1/2CCC
Humax-Cd20
Tianjin Medical University General Hospital
D
Calculus Bovis Sativus
Tongji Hospital
N/ANR

Same molecule, other indications

OPICINUMAB is also rated in:

multiple sclerosisDormant
CCC
Indicative ·
55 / 100
View asset →
optic neuritisDormant
CC
Indicative ·
47 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →